newsfilter
← Latest News
GlobeNewswire·

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy of Cancer